Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cafosa is a leading global supplier of gum base for the confectionery and pharmaceutical industries. As a subsidiary of Mars Wrigley, the company specializes in developing and manufacturing gum bases that serve as delivery systems for active pharmaceutical ingredients (APIs) and nutraceuticals. Their Health & Gum division provides specialized solutions for medicated chewing gum, offering a patient-friendly alternative to traditional oral dosage forms. Cafosa's expertise includes formulation support, regulatory compliance, and large-scale manufacturing of gum-based products for indications such as smoking cessation and oral hygiene. The company operates under strict GMP standards to ensure the quality and safety of its pharmaceutical-grade excipients.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cafosa.